Literature DB >> 31976778

Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic.

Rajiv Balyan1,2, David Hahn2, Henry Huang1, Vidya Chidambaran1,3.   

Abstract

Introduction: Opioids continue to be used widely for pain management. Widespread availability of prescription opioids has led to opioid abuse and addiction. Besides steps to reduce inappropriate prescribing, exploiting opioid pharmacology to make their use safer is important.Areas covered: This article discusses the pathology and factors underlying opioid abuse. Pharmacokinetic and pharmacodynamic properties affecting abuse liability of commonly abused opioids have been highlighted. These properties inform the development of ideal abuse deterrent products. Mechanisms and cost-effectiveness of available abuse deterrent products have been reviewed in addition to the pharmacology of medications used to treat addiction.Expert opinion: The opioid crisis presents unique challenges to managing pain effectively given the limited repertoire of strong analgesics. The 5-point strategy to combat the opioid crisis calls for better preventive, treatment, and recovery services, better data, better pain management, better availability of overdose-reversing drugs and better research. There is an urgent need to decrease the cost of abuse deterrent opioids which deters their cost-effectiveness. In addition, discovery of novel analgesics, further insight into central and peripheral pain mechanisms, understanding genomic risk profiles for efficient targeted efforts, and education will be key to winning this fight against the opioid crisis.

Entities:  

Keywords:  Opioid crisis; abuse deterrent product; pain pharmacology; pk-PD

Mesh:

Substances:

Year:  2020        PMID: 31976778      PMCID: PMC7199505          DOI: 10.1080/17425255.2020.1721458

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  126 in total

1.  JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations.

Authors:  D M Phillips
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

2.  The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk.

Authors:  H Zhang; H R Kranzler; B-Z Yang; X Luo; J Gelernter
Journal:  Mol Psychiatry       Date:  2007-07-10       Impact factor: 15.992

3.  Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.

Authors:  L A Marsch; W K Bickel; G J Badger; J P Rathmell; M D Swedberg; B Jonzon; C Norsten-Höög
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

4.  The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

Authors:  Lisa S Middleton; Paul A Nuzzo; Michelle R Lofwall; David E Moody; Sharon L Walsh
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

Review 5.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

6.  Naltrexone metabolism and concomitant drug concentrations in chronic pain patients.

Authors:  Janet C Liu; Joseph D Ma; Candis M Morello; Rabia S Atayee; Brookie M Best
Journal:  J Anal Toxicol       Date:  2014-03-21       Impact factor: 3.367

7.  Alprazolam absorption kinetics affects abuse liability.

Authors:  G K Mumford; S M Evans; J C Fleishaker; R R Griffiths
Journal:  Clin Pharmacol Ther       Date:  1995-03       Impact factor: 6.875

Review 8.  Cryoneurolysis for the Treatment of Sensory Nerve Pain.

Authors:  Alison Smiley; Jason McGuire
Journal:  AANA J       Date:  2018-12

9.  Familial transmission of substance use disorders.

Authors:  K R Merikangas; M Stolar; D E Stevens; J Goulet; M A Preisig; B Fenton; H Zhang; S S O'Malley; B J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  1998-11

10.  Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.

Authors:  J Bradford Rice; Noam Y Kirson; Amie Shei; Alice Kate G Cummings; Katharine Bodnar; Howard G Birnbaum; Rami Ben-Joseph
Journal:  Appl Health Econ Health Policy       Date:  2014-08       Impact factor: 2.561

View more
  1 in total

1.  Oxycodone self-administration activates the mitogen-activated protein kinase/ mitogen- and stress-activated protein kinase (MAPK-MSK) signaling pathway in the rat dorsal striatum.

Authors:  Christopher A Blackwood; Michael T McCoy; Bruce Ladenheim; Jean Lud Cadet
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.